Classic Congenital Adrenal Hyperplasia (CAH): Crinecerfont Coverage
Customize your policy alerts
Sign up for Molina Healthcare Policy C29356-A alerts
Get alerted when Policy C29356-A changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization and coverage of oral crinecerfont (Crenessity) for adults and pediatric patients at least 4 years old with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Coverage requires documented adjunctive glucocorticoid use, stable supraphysiologic glucocorticoid dosing, applicable formulation criteria, and involvement by a board-certified endocrinologist.
New coverage criteria were created in Q2 2025.
An Appendix revision was identified in Q3 2026.
The available dosage forms section was revised in Q3 2025.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.